Archives of dermatological research · 2025
Tetrandrine induces cell cycle arrest in cutaneous melanoma cells by inhibiting IL-6/CDC42 signaling.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Niu Liang, Chang Jin, Liu Shuo, Shen Jiuxiao, Li Xiaojing, Guo Yangui, Zhang Ling
Аннотация
BACKGROUND: Cutaneous melanoma (CM) is a skin melanocytes-derived malignant tumor accounting for most of the death in skin cancers. The clinical drug for CM is limited or with poor efficacy. Tetrandrine is a natural alkaloid with diverse pharmacological effects including anti-cancer. This study investigated the anti-cancer potential and mechanisms of tetrandrine in CM, which might provide more therapeutic options for CM.
METHODS: The effects of tetrandrine on CM cell proliferation were evaluated via CCK8 and colony formation assay. The cell cycle analysis was conducted by flow cytometry. qRT-PCR and western blotting were performed to determine relevant RNA and protein levels. Co-Immunoprecipitation assay was used to detect the protein-protein interaction. Small interfering RNA transfection or lentiviral transduction were used to knockdown or overexpress target proteins, respectively.
RESULTS: Tetrandrine triggered a significant G0/G1 cell cycle arrest in A375 and SK-MEL-2 cells. Tetrandrine decreased the expression of the cell cycle activator cyclin D1 and increased cell cycle inhibitor p21. In-depth study revealed that the anti-CM activities of tetrandrine mainly dependent on Interleukin-6 (IL-6) and cell division cycle 42 (CDC42) regulation. A direct interaction between IL-6 and CDC42 was identified. Tetrandrine suppressed IL-6 expression and subsequently inhibited CDC42, which in turns lead to G0/G1 cell cycle arrest in CM cells.
CONCLUSION: Tetrandrine suppressed CM cell growth by triggering G0/G1 cell cycle arrest via IL-6/CDC42 inhibition. Tetrandrine should be a promising compound for CM treatment.
METHODS: The effects of tetrandrine on CM cell proliferation were evaluated via CCK8 and colony formation assay. The cell cycle analysis was conducted by flow cytometry. qRT-PCR and western blotting were performed to determine relevant RNA and protein levels. Co-Immunoprecipitation assay was used to detect the protein-protein interaction. Small interfering RNA transfection or lentiviral transduction were used to knockdown or overexpress target proteins, respectively.
RESULTS: Tetrandrine triggered a significant G0/G1 cell cycle arrest in A375 and SK-MEL-2 cells. Tetrandrine decreased the expression of the cell cycle activator cyclin D1 and increased cell cycle inhibitor p21. In-depth study revealed that the anti-CM activities of tetrandrine mainly dependent on Interleukin-6 (IL-6) and cell division cycle 42 (CDC42) regulation. A direct interaction between IL-6 and CDC42 was identified. Tetrandrine suppressed IL-6 expression and subsequently inhibited CDC42, which in turns lead to G0/G1 cell cycle arrest in CM cells.
CONCLUSION: Tetrandrine suppressed CM cell growth by triggering G0/G1 cell cycle arrest via IL-6/CDC42 inhibition. Tetrandrine should be a promising compound for CM treatment.